Johnson & Johnson (JNJ.US) / Legend Biotech (LEGN.US) CAR-T therapy has achieved positive results in phase III.

According to the news from the Securities Times app, on July 3, Johnson & Johnson (JNJ.US) and Legend Biotech (LEGN.US) jointly announced the positive results of the planned second interim analysis of the Phase 3 CARTITUDE-4 study. The study evaluated the chimeric antigen receptor (CAR) T cell therapy Carvykti jointly developed by the two companies, compared to standard therapy, for the treatment of patients with relapsed or refractory multiple myeloma (MM) who are resistant to lenalidomide after 1st-line treatment. The interim analysis showed that compared with standard therapy, patients treated with Carvykti had a longer overall survival.

Zhitong Finance10:03

Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval

By Michael Susin Johnson & Johnson said the Canadian health authority issued a notice of compliance for its lung-cancer treatment, meaning the drug is authorized to be marketed under certain conditio

WSJ7minutes ago

Express News | Health Canada Authorizes Rybrevant® (Amivantamab) in Combination With Carboplatin and Pemetrexed as the Only Targeted First-Line Treatment Approved for Patients With Non-Small Cell Lung Cancer With Egfr Exon 20 Insertion Mutations

Breakings35minutes ago

China International Capital Corporation: Colored contact lenses promote demand upgrade, and manufacturing business enters the golden development period.

Terminal demand upgrades, technological innovation, and changes in the market landscape will drive rapid development in the domestic industry chain. Contact lenses and colored contact lenses will usher in new development opportunities and are expected to continue to maintain a strong growth trend in the next few years.

Zhitong Finance09:54

Express News | Johnson & Johnson has received approval from the US Food and Drug Administration and the European Commission for SIRTURO (bedaquiline), a pharmaceutical.

Breakings07:48

Express News | Johnson & Johnson Receives Approval From U.S. FDA and European Commission for Sirturo® (Bedaquiline)

Breakings07:46